相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group
Ermond van Beek et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats
T.J. Wronski et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro
Zachary J. Henneman et al.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A (2008)
Fracture risk remains reduced one year after discontinuation of risedronate
N. B. Watts et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs
M. R. Allen et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: Review of statistical analysis - Response
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Using real-world data for coverage and payment decisions: The ISPOR real-world data task force report
Louis P. Garrison et al.
VALUE IN HEALTH (2007)
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
Michael McClung et al.
BONE (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading
Helene Follet et al.
BONE (2007)
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis
Florence Daubine et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
S. L. Silverman et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: Results of a double-blind, placebo-controlled randomized study
Eugene V. McCloskey et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Solid-state NMR, crystallographic, and computational investigation of Bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes
Junhong Mao et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
Hip and non-spine fracture risk reductions differ among antiresorptive agents: evidence from randomised controlled trials
U. A. Liberman et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Bone material properties in trabecular bone from human iliac crest biopsies after 3-and 5-year treatment with risedronate
Erich Durchschlag et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs
Lilian I. Plotkin et al.
BONE (2006)
The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding
Kathryn L. Kavanagh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men
Joel S. Finkelstein et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years
Sydney Bonnick et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
The molecular mechanism of nitrogen-containing bisphosphonates as anti osteoporosis drugs
Kathryn L. Kavanagh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis
K Thompson et al.
MOLECULAR PHARMACOLOGY (2006)
Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite
G. H. Nancollas et al.
BONE (2006)
Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy
Chih-Tai Leu et al.
BONE (2006)
Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases
JE Dunford et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss
JI Aguirre et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs
Jean-Michel Rondeau et al.
CHEMMEDCHEM (2006)
Anti-hip fracture efficacy of bisphosphonates: A Bayesian analysis of clinical trials
ND Nguyen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates
H Mönkkönen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Recent advances in understanding the mechanism of action of bisphosphonates
Fraser P. Coxon et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: Reduction in risk of nonvertebral fracture is not related to change in BMD
NB Watts et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Osteogenesis imperfecta, current and future medical treatment
F Rauch et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS (2005)
Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model
DG Little et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis
D Felsenberg et al.
BONE (2005)
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies
S Boonen et al.
OSTEOPOROSIS INTERNATIONAL (2005)
The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis - A randomized clinical study
KA Lai et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2005)
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease
IR Reid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats
AHA Kurth et al.
BONE (2005)
The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: Correlation to histomorphometric indices of turnover
B Borah et al.
BONE (2005)
Zoledronic acid improves femoral head sphericity in a rat model of perthes disease
DG Little et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2005)
Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women
SE Papapoulos et al.
OSTEOPOROSIS INTERNATIONAL (2005)
The role of bisphosphonates in the treatment of prostate cancer
CC Parker
BJU INTERNATIONAL (2005)
Severely suppressed bone turnover: A potential complication of alendronate therapy
CV Odvina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
TREATMENT WITH ONCE-WEEKLY ALENDRONATE 70 MG COMPARED TO ONCE-WEEKLY RISEDRONATE 35 MG IN WOMEN WITH POSTMENOPAUSALE OSTEOPOROSIS: A RANDOMIZED DOUBLE-BLIND STUDY
Peter Pietschmann
JOURNAL FUR MINERALSTOFFWECHSEL (2005)
The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib
T Mashiba et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2005)
Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial
JM Wilkinson et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2005)
Efficacy of risedronate on clinical vertebral fractures within six months
C Roux et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis
JT Harrington et al.
CALCIFIED TISSUE INTERNATIONAL (2004)
Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy
PD Delmas et al.
BONE (2004)
Ten years' experience with alendronate for osteoporosis in postmenopausal women
HG Bone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis
DJ Hosfield et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Statins prevent bisphosphonate-induced γ,δ-T-cell proliferation and activation in vitro
K Thompson et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate
NB Watts et al.
JOURNAL OF CLINICAL DENSITOMETRY (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
From molds and macrophages to mevalonate: A decade of progress in understanding the molecular mode of action of bisphosphonates
MJ Rogers
CALCIFIED TISSUE INTERNATIONAL (2004)
Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing
F Bauss et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis
G Kogianni et al.
LIFE SCIENCES (2004)
Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients
R Recker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis:: Results of a double-blind, placebo-controlled 3-year study
E McCloskey et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Brief report: Bisphosphonate-induced osteopetrosis
MP Whyte et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis
DG Little et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate
R Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates
ER van Beek et al.
BONE (2003)
Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats
DG Little et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis
EF Eriksen et al.
BONE (2002)
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
TL Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Daily oral pamidronate in women and men with osteoporosis: A 3-year randomized placebo-controlled clinical trial with a 2-year open extension
C Brumsen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Further insight into mechanism of action of clodronate:: Inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite
PP Lehenkari et al.
MOLECULAR PHARMACOLOGY (2002)
Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption
JR Green et al.
DRUG DEVELOPMENT RESEARCH (2002)
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
IR Reid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix γ-carboxyglutamic acid protein in the serum of etidronate-treated rats
PA Price et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis
S Cremers et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Risedronate reduces the risk of first vertebral fracture in osteoporotic women
RP Heaney et al.
OSTEOPOROSIS INTERNATIONAL (2002)
Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
HL Benford et al.
BONE (2001)
Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration
DY Mitchell et al.
PHARMACEUTICAL RESEARCH (2001)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
FP Coxon et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
JD Bergstrom et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2000)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
分享论文
